Ocular Hydrogel TKI Implants for Sustained Retinal Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ocular drug delivery methods for treating macular degeneration, particularly wet AMD, face challenges such as systemic side effects from TKIs, ineffective ocular instillation, rapid clearance, and complications from intravitreal injections, along with issues related to biodegradable implants like drug dumping and residual implant residues.
Innovation Solution
Development of biodegradable ocular hydrogel implants containing a tyrosine kinase inhibitor (TKI) with a polymer network and a clearance zone, designed to solubilize and release TKI effectively, preventing undissolved particles from contacting retinal cells and ensuring complete degradation without residues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intravitreal injection is used to deliver TKI, then therapeutic ocular drug levels can be achieved, but the treatment requires daily injections which is not tolerable to many patients
Solution Approach 1:
The TKI is pre-loaded into the hydrogel implant matrix during manufacturing, creating a reservoir that gradually releases the drug over time. This preliminary preparation eliminates the need for repeated daily injections while maintaining therapeutic drug levels in the ocular tissue for extended periods
Solution Approach 2:
The hydrogel implant provides dynamic, sustained drug release through its polymer network structure that gradually degrades and releases TKI at controlled rates. This dynamic release mechanism maintains therapeutic levels without requiring frequent re-administration, transforming the static daily injection protocol into a progressive release system
2Duration of action of moving object
If hydrophobic drugs are formulated with biodegradable matrices in ocular implants, then sustained release is achieved, but high initial drug burst or very little release until erosion occurs can result
Solution Approach 1:
The hydrogel matrix parameters are specifically engineered to control drug release kinetics. By adjusting the polymer network density, crosslinking degree, and hydrogel composition, the release profile is optimized to prevent both burst release and delayed release, achieving consistent sustained release of TKI throughout the implant duration
Solution Approach 2:
The implant uses a composite hydrogel structure combining hydrophilic and hydrophobic polymer components that work synergistically. The hydrophilic network provides water uptake and swelling for controlled release, while the hydrophobic domains maintain drug loading and prevent premature release, together achieving reliable sustained release without burst or delay
3Duration of action of stationary object
If ocular implants are placed in the eye for chronic therapy, then treatment duration is extended, but accumulation of empty implants or requirement for removal procedures occurs
Solution Approach 1:
The implant is designed as a single-use, biodegradable device that completely degrades after delivering its drug payload. This disposable approach eliminates the need for removal procedures and prevents accumulation of empty implants, as each implant naturally dissolves and is eliminated by the body's metabolic processes after completing its therapeutic function
4Stability of the object's composition
If non-biodegradable ocular implants are used, then implant structure stability is maintained, but accumulation of empty implants or removal procedures are required
Solution Approach 1:
The biodegradable hydrogel implant performs self-service by automatically degrading and eliminating itself after drug delivery. The polymer network is designed to break down into metabolically compatible fragments that are naturally cleared by the body, making the implant self-eliminating and preventing accumulation without requiring external removal intervention
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hydrogel implants provide sustained release of TKI for at least six months, effectively treating vascular endothelial growth factor-induced retinal leakage with minimal side effects and no residual implant matter, as depicted in the exemplification section.
Implementation Method 1
the TKI is present in the hydrogel at or near saturation level
Implementation Method 2
the rate of TKI release from the hydrogel is controlled by the drug solubility in the hydrogel matrix
Implementation Method 3
The disclosed hydrogel implants are designed to be fully biodegradable, e.g., residual particulate matter or floaters are not of concern
Data Source
AI summary
Provided herein are sustained-release biodegradable ocular hydrogel implants which are useful in the treatment of certain ocular conditions.